PreciseDx, the leading innovator behind PreciseBreast, a novel breast cancer diagnostic that is powered by OncoIntelligence, their proprietary AI-platform, announced the successful closing of $11 million in funding and two key leadership hires.

PreciseDx 是 PreciseBreast 背后的领先创新者，PreciseBreast 是一种由其专有的人工智能平台 OncoIntelligence 支持的新型乳腺癌诊断方法。该公司宣布成功完成 1100 万美元的融资，并聘请了两名关键领导职位。

This latest round of funding was led by Eventide Asset Management, Merck Global Health Innovation Fund and Philips Ventures and included Labcorp, Quest Diagnostics, GenHenn Capital Venture, along with other existing investors. This funding will help prioritize the company's ongoing clinical data collection, commercial expansion and planning for the 2026 launch of its flagship product, PreciseBreast..

最新一轮融资由Eventide资产管理公司、默克全球健康创新基金和飞利浦风险投资公司领投，Labcorp、Quest Diagnostics、GenHenn Capital Venture以及其他现有投资者参投。这笔资金将有助于优先推进公司正在进行的临床数据收集、商业扩展以及计划于2026年推出的旗舰产品PreciseBreast的相关规划。